CHECKPOINT THERAPEUTICS



NASDAQ: CKPT

CORPORATE PRESENTATION

April 2019



FORWARD LOOKING SAFE HARBOR STATEMENT

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", expects", plans", believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause Checkpoint Therapeutics' actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Checkpoint Therapeutics undertakes no obligation to update these statements, except as required by law.

Oncology Product Portfolio: Solid Tumor Focus



EGFR Mutation-Positive NSCLC: Well-Validated Target

- 1st and 2nd generation EGFR inhibitors lead to acquired resistance to therapy, mainly due to T790M resistance mutation

- 3rd generation EGFR inhibitors target EGFR activating mutations and T790M resistance mutation leading to longer responses

  – Tagrisso® (osimertinib) is only marketed 3rd gen inhibitor with a projected market oppty >$6 billion annually

    - Warnings and precautions: QTc prolongation (4.5%), interstitial lung disease (3.9%), cardiomyopathy (2.6%)

    - Ph 3 (FLAURA) study AEs: diarrhea (58%), rash (58%), dry skin (36%), nail toxicity (35%), stomatitis (29%)

      ➢ 13% of pts permanently discontinued due to AEs

CK-101: 3RD GENERATION, IRREVERSIBLE MUTANT-SELECTIVE EGFR INHIBITOR

- In mice, CK-101 showed strong activity against EGFR (T790M) mutant NSCLC with increasing dose.

T790M NSCLC xenograft model



Poster: AACR Annual Meeting 2017

CK-101: 3RD GENERATION, IRREVERSIBLE MUTANT-SELECTIVE EGFR INHIBITOR

- In mice, CK-101 showed no activity against <u>wild-type (normal) EGFR</u> with increasing dose.

WT EGFR xenograft model



Poster: AACR Annual Meeting 2017

CK-101: Ongoing Phase 1 Clinical Study



Oral Presentation World Conference on Lung Cancer (WCLC)
Sept 2018

CK-101 Phase 1 Interim Data
Safety: Emerging Differentiation

- CK-101 was well-tolerated
  - Most adverse events were Grade 1-2
  - No DLTs or treatment-related SAEs

- **No events of:**
  - Interstitial lung disease (ILD)
  - Pneumonitis
  - QTc prolongation
  - Cardiomyopathy
  - Nail toxicities
  - Stomatitis
  - Hyperglycemia

Most Common (≥3pts) Treatment-Related Adverse Events, n (%)	All Patients Treated (N=37)		
	All Grades	Grade 3	Grade 4
Nausea	6 (16%)	-	-
Diarrhea	5 (14%)	1 (3%)	-
Lacrimation incr.	5 (14%)	-	-
Vomiting	4 (11%)	-	-
Bilirubin incr.	3 (8%)	2 (5%)	-
Rash	3 (8%)	2 (5%)	-
ALT incr.	3 (8%)	1 (3%)	-
AST incr.	3 (8%)	1 (3%)	-
Pruritus	3 (8%)	1 (3%)	-
Dysphonia	3 (8%)	-	-
Hypoesthesia	3 (8%)	-	-

Oral Presentation: World Lung Sept 2018
Data cutoff: June 2018

CK-101 Phase 1 Interim Data Efficacy

- Confirmed ORR: 53% (10/19)
  - 75% (6/8) treatment-naïve pts achieved partial response
    - Phase 3 target population
  - 84% (16/19) pts had target lesion reductions versus baseline
  - 100% (19/19) DCR
- 60% (3/5) pts with brain mets at baseline achieved PR with intracranial reductions



Interim response data as of November 2018.

CK-101: Planned Phase 3 Study Design

Similar design as used by Tagrisso®



2019 initiation: ~24 months to enroll and reach PFS endpoint

CK-301: ANTI-PD-L1

- Fully human IgG1 monoclonal antibody that binds PD-L1
  - PD-1/L1 mAbs expected to sell >$40B annually
- Licensed from Dana-Farber Cancer Institute
  - Binding affinity optimized by Adimab to compete with best-in-class approved antibodies
  - Differentiation: Half-life supports sustained >99% target occupancy with additional potential to induce antibody-dependent cell-mediated cytotoxicity (ADCC) for enhanced anti-tumor activity
- Development strategy:
  - Pursue accelerated approval indications (endometrial/CRC)
  - Demonstrate activity in large established indications (NSCLC)
- Commercial strategy: Market disrupting pricing

CK-301: High Affinity Binding to PD-L1

Target Protein	Antibody	KD (M)	kon(1/Ms)	kdis(1/s)
huPDL1	CK-301	8.47E-10	7.20E+05	6.10E-04
cynoPDL1	CK-301	5.55E-10	1.14E+06	6.35E-04
huPDL1	atezolizumab*	2.02E-09	4.52E+05	9.11E-04
cynoPDL1	atezolizumab*	8.95E-09	6.10E+05	5.46E-03

ELISA on PD-L1 coated plates



FACS with PD-L1+ cells



Poster: AACR Annual Meeting 2017

* surrogate

CK-301: Phase 1 Clinical Study in Advanced Cancers (I-O Naïve)

- Interim safety and efficacy data expected in 2Q 2019



1 Potential accelerated approval indications. MSI-H: microsatellite instability-high. dMMR: DNA mismatch repair deficient.

RECENT PD-(L)1 LICENSING DEALS


ENDPOINTS NEWS

Wednesday, October 25, 2017

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics


FierceBiotech

Celgene bags Beigene PD-1 drug for $263M up front

- Incyte buys exclusive worldwide rights to Phase 1 anti-PD-1
- MacroGenics receives:
  - $150MM upfront
  - $420MM in development milestones
  - $330MM in commercial milestones
  - Royalties: 15-24% of sales
  - Right to use the anti-PD-1 in combination with other pipeline products

- Celgene buys ex-Asia solid tumor rights to early Phase 3 anti-PD-1
- Beigene receives:
  - $413MM upfront ($263MM cash / $150MM stock)
  - $1B in milestones
  - Royalties: up to ~25% of sales
  - Celgene's commercial operations in China, including three approved products

KEY TAKEAWAYS

- Lead EGFR inhibitor and anti-PD-L1 programs enrolling expansion cohorts with clinical activity observed
- CK-101 (EGFRi): interim data presented at World Lung; add'l data and commencement of registration study in 2019
- CK-301 (anti-PD-L1): interim data in 2Q 2019; pursuing rapid accelerated approvals in indications with high unmet need
- Exploring potential proprietary combinations with PD-L1 backbone (e.g., PD-L1 combo w EGFRi)

CHECKPOINT THERAPEUTICS



NASDAQ: CKPT

CORPORATE PRESENTATION

April 2019